Imagine this: In a quiet facility out of sight from prying eyes, a surgeon implants a heart in a patient in urgent need of a transplant. The amazing aspect? This heart was not given, removed, or shipped on ice. It was built, layer by layer, through state-of-the-art bioprinting capabilities. But this scientific miracle does not take place under hospital lights, rather in obscurity—illicit operations. Can this dystopian scenario become a reality?

Scientists at Boston University shocked the globe by employing 3D printing techniques to craft a miniature human heart. Miraculously, this mini heart beats on its own, without an outside power source. Composed of stem cell-derived human heart cell components and microscale 3D-printing acrylic components, it’s a revolutionary step forward for medicine. These advancements hold revolutionary potential: tracing embryonic heart development, examining how diseases affect cardiac tissue, and safely experimenting with new drugs without putting human subjects at risk.

However, looking forward, bioprinting’s potential is not just for research. It holds out hope as a lifesaving answer to the shortage of organ donors on a global level. The World Health Organization (WHO) states that millions of people are on waiting lists for organ transplants, with thousands every year losing their lives because no donor was available. These tragic shortages can be ended by bioprinting, with an organ always on hand—made to order, with precisely matched tissues.

But with most major advances in technology come ethical gray areas. Will bioprinting technology feed an illicit black market, generating new ethical dilemmas?

History gives us a sobering reminder about human ingenuity’s double-edged nature. The history of Fritz Haber, a Nobel prize-winning scientist credited with inventing synthetic fertilizers, is an example. Haber’s invention transformed agriculture, saving millions from starvation. The same science also enabled the production of chemical weapons and bombs deployed in war. Haber’s case is a prime illustration of how innovative technology can prove both a blessing and curse.

Bioprinting also has a comparable choice to make. Its potential to save scores of lives is irrefutable. But without robust regulation and ethical control, it may unintentionally empower crime gangs intending to take advantage of desperate people in need of an organ quickly, cutting out the long and regulated waiting lists of proper healthcare systems.

Envision a rich person in urgent need of a kidney. Instead of waiting months or years, they may have recourse to shadowy labs with a quick fix—nigh-on over-night bioprinted organs. Given high demand invariably and regulation invariably behind, black-market players may prosper.

Ethicist Dr. Jonathan Moreno cautioned, “Technology always gets ahead of ethics and legislation. It’s an aspect of progress, but we can’t afford to be complacent.” This observation strongly points out the possible weak points as bioprinting technology proceeds at a rapid pace.

Popular culture reflects on this scenario in science fiction movies like “Repo Men” where there is brutal repossession of artificial organs when payment is missed. Dramatized as it is, such dystopian visions strongly reflect potential crises in ethics that come about with influential technologies without strong regulation.

Still, optimism must not give way entirely to alarm. Look at the “Two Wolves” parable commonly traced back to Cherokee tradition, in which an elderly sage instructs his grandson on how good and evil battle inside every human. When asked to identify the victor, the sage sagely responds, “The one you feed.” Society has an analogous decision to make with bioprinting technology: feed its better aspects or abandon its worst potential?

The global community needs to push forward with unambiguous ethical standards, regulatory protocols, and tight controls. Open scrutiny will deter exploitation as it encourages safe, available advances in medicine. Public health education can further reduce black-market attractiveness by making these technologies widely available and accessible to all.

Dr. Anthony Atala, a leader in bioprinting and director of the Wake Forest Institute for Regenerative Medicine, embodies the spirit of ethical innovation most effectively: “Our objective is not only to create these technologies, but to create them in a manner respectful to human dignity and justice.”

Ultimately, bioprinting can truly revolutionize medicine, transforming possibilities and saving innumerable lives. Yet, vigil is key. Society needs to address and control the ethical dilemmas in advance to avoid medicine’s savior technologies from becoming dark misuses. While we are at the brink of amazing advances in medicine, let us make sure that bioprinted organs create hope and life under regulatory watch—fear or exploitation on backstreets of the black market is not an option.

Dr. Prahlada N.B
MBBS (JJMMC), MS (PGIMER, Chandigarh). 
MBA in Healthcare & Hospital Management (BITS, Pilani), 
Postgraduate Certificate in Technology Leadership and Innovation (MIT, USA)
Executive Programme in Strategic Management (IIM, Lucknow)
Senior Management Programme in Healthcare Management (IIM, Kozhikode)
Advanced Certificate in AI for Digital Health and Imaging Program (IISc, Bengaluru). 

Senior Professor and former Head, 
Department of ENT-Head & Neck Surgery, Skull Base Surgery, Cochlear Implant Surgery. 
Basaveshwara Medical College & Hospital, Chitradurga, Karnataka, India. 

My Vision: I don’t want to be a genius.  I want to be a person with a bundle of experience. 

My Mission: Help others achieve their life’s objectives in my presence or absence!

My Values:  Creating value for others. 

Leave a reply